Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Ignyta Reports Granting of Inducement Awards

Posted on: 16 Nov 17

Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that it has issued two inducement awards to new non-executive employees.

The awards were made on November 15, 2017, under Ignyta’s 2017 Employment Inducement Equity Incentive Award Plan, which was adopted on August 17, 2017, and provides for the granting of equity awards to new employees of Ignyta. The inducement awards were not individually negotiated and consist of options to purchase an aggregate of 65,000 shares of Ignyta common stock and each has a ten-year term. The exercise price of the options was $15.00, which was the per-share closing price of Ignyta’s common stock on the Nasdaq Capital Market on November 15, 2017. Each option vests over a four-year period, with 25% vesting on the first anniversary of the date of hire and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Ignyta’s board of directors and were granted as inducements material to the new employees entering into employment with Ignyta in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Ignyta, Inc.

Blazing a New Future for Patients with Cancer™

At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular and immunological drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with rare cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class or best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.

For more information, please visit:

View source version on

Business Wire

Last updated on: 16/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.